Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bronchitis pill aims to quiet coughs faster

NCT ID NCT07198347

Symptom relief Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an experimental drug called AG2001 in 300 adults with acute bronchitis. Participants take the drug three times daily for 7 days. The goal is to see if AG2001 reduces cough and mucus better than two other active drugs by day 4. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AG2001 (an experimental drug for bronchitis)
What this could lead to
If successful, AG2001 could offer a new treatment option that reduces cough and mucus in acute bronchitis more effectively than current medications.
What could go wrong
This is an early Phase 3 trial with only 300 participants, so results may not apply to everyone. The drug may not prove superior to existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥19 years to \<65 years old 2. Subjects who present symptoms of Acute Bronchitis with cough and sputum symptoms within 48 hours prior the randomization visit(Visit 2) who satisfy the following * Total Bronchitis Severity Scale ≥ 5 * Total Bronchitis Severity Scale sputum score ≥ 2 3. Subjects who without fever(condensed body temperature standard: less than 38.5°C) prior to randomization visit(Visit 2) 4. Subjects who present symptoms of Acute Bronchitis with cough less then 2 weeks prior to randomization visit(Visit 2) 5. Written consent voluntarily to participate who can understand the information provided in this clinical trial Exclusion Criteria: * Chronic respiratory diseases (e.g., COPD, asthma, pneumonia, tuberculosis, lung cancer) * Clinically significant hepatic, renal, cardiovascular, or neurological disorders * Use of prohibited medications (e.g., antibiotics, antivirals, corticosteroids) within the washout period * Positive test for hepatitis B, hepatitis C, or HIV * Pregnant or breastfeeding women * Any condition deemed inappropriate by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchitis Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute bronchitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.